



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Label No. E16351073675 US with sufficient postage on the date indicated below and in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

[X] If checked, two copies of this correspondence are enclosed.

Dawn M Janelle
 Signature

Date of Deposit: NOV. 18, 2005

Dawn M. Janelle

Printed name of person mailing correspondence

Applicant:	DONG, Zheng Xin	Art Unit:	Unknown
Serial No.:	10/554,240	Examiner:	Unknown
Filed:	Oct. 21, 2005		
Title:	SOMATOSTATIN VECTORS		

**INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO
 CHARGE DEPOSIT ACCOUNT**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- [] under 37 CFR 1.129(a), or
 (First/Second submission after Final Rejection)
- [X] under 37 CFR 1.97(b), or
 (Whichever occurs last of the following: within three months of filing national application; within three months of date of entry of the national stage in international application; before the mailing date of first office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination)
- [] under 37 CFR 1.97(c) together with either:
 - [] a Statement under 37 CFR 1.97(e), as checked below, or
 - [] a \$180.00 fee under 37 CFR 1.17(p), or
 (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- [] under 37 CFR 1.97(d) together with:
 - [] a Statement under 37 CFR 1.97(e), as checked below, and
 - [] a Petition under 37 CFR 1.97(d)(2), and
 - [] a \$130.00 petition fee set forth in 37 CFR 1.17(i).
 (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)
- [] Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper.
 (Filed after payment of issue fee)
- [X] Some of the listed references were cited in a European Search Report in a counterpart European application or cited in a communication from a foreign patent office in a counterpart foreign application.

[] Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of each reference noted thereon.

[X] Enclosed herewith is form PTO/1449 (1 page; reproduced form), with a copy of selected references noted thereon. As per the change to 37 CFR 1.98(a)(2) published in the September 21, 2004 Federal Register and effective as of October 21, 2004, in which the requirement for a copy of each U.S. Patent or U.S. Patent application publication listed in an IDS has been eliminated regardless of the filing date of the application (unless required by the Office), copies of any United States Patent or Patent Publications are not enclosed.

[] Copies of the reference(s) noted on the enclosed form PTO/1449 (N pages, reproduced form) were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)). Applicants request that copies of art in U.S. Application Serial No. [] cited on the enclosed PTO/1449 form be transferred to the present U.S. Application Serial No. [].

Concise Explanation Requirement (non-English references):

[] The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

[] the explanation provided on the attached sheet.

[] the explanation provided in the Specification.

[] submission of the enclosed International Search Report.

[] the enclosed English language abstracts.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO/SB/08B appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Statement Under 37 CFR 1.97(e):

[] Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.

[X] No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.

[X] The Commissioner is hereby authorized to charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,
BIOMEASURE, INCORPORATED

By Pamela C. Ball

Pamela C. Ball, Agent for Applicant(s)
Registration No.: 53,963

Dated: Nov 18 2005
27 Maple Street
Milford, Massachusetts 01757
Phone: (508)478-0144
Facsimile: (508) 473-3531

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
119P/PCT2/USAPPLICATION NO.
10/554,240

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

APPLICANT
DONG, Zheng XinFILING DATE
Oct. 21, 2005GROUP/EXAMINER
Unknown/Unknown

U. S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A	5,482,698	Jan. 9, 1996	Griffiths			
	B	5,525,338	Jun. 11, 199	Goldenberg			
	C	5,795,909	Aug. 18, 1998	Shashoua et al.			
	D	5,843,903	Dec. 1, 1998	Schally et al.			
	E	5,948,750	Sep. 7, 1999	Garsky et al.			
	F	6,077,499	Jun. 20, 2000	Griffiths et al.			
	G	6,191,290	Feb. 20, 2001	Safavy			
	H	6,207,660	Mar. 27, 2001	Sessler et al.			
	I	2002 0094964	Jul. 18, 2002	Chen et al.			
	J	2002 0115596	Aug. 22, 2002	Garsky et al.			
	K	2003 0064053	Apr. 3, 2003	Liu et al.			
	L	2003 0064984	Apr. 3, 2003	Ng et al.			
	M	2005 0070470	Mar. 31, 2005	Coy et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	N	96/40210	Dec. 19, 1996	WIPO PCT			
	O	97/19954	Jun. 5, 1997	WIPO PCT			
	P	02/34237	May 2, 2002	WIPO PCT			
	Q	02/87497	Nov. 7, 2002	WIPO PCT			
	R	0 450 461 (A2, A3, B1)	Oct. 9, 1991	EP			
	S	0 450 480 (A2, A3, B1)	Oct. 9, 1991	EP			
	T	1 118 336	Jul. 25, 2001	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	U	FUSELIER, et al., "An adjustable release rate linking strategy for cytotoxin-peptide conjugates," Bioor. Med. Chem. Lett., 2003, 10:799-803.
	V	HUANG, et al., "Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis," Chem. Biol., 2000, 7:453-461.
	W	KOVACS, et al., "Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone," PNAS, 1997, 94:1420-1425.
	X	NAGY, et al., "Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin," PNAS, 95:1794-1799.
	Y	SAFAVY, et al., "Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery," Bioconjug. Chem., 2003, 14:302-310

EXAMINER	DATE CONSIDERED
----------	-----------------

